Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer.
Radiolabeled lipiodol has been used for targeting liver cancer. We developed a lipiodol solution of (188)Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol) and investigated its feasibility for the treatment of liver cancer. The lipiodol solution of (188)Re-TDD was well-retained in the lipiodol phase in vitro. After injection through the tail veins of mice, high lung-uptake was investigated which is evidence of embolizing activity. We also found high accumulation in hepatoma after injection through the hepatic arteries of hepatoma-bearing rats. In conclusion, the lipiodol solution of (188)Re-TDD is a promising agent for liver cancer therapy.
Jeong
J M
JM
Department of Nuclear Medicine, Seoul National University, 28 Yungun-dong Chongro-ku, Seoul 110-744, Korea. jmjng@snu.ac.kr
Kim
Y J
YJ
Lee
Y S
YS
Ko
J I
JI
Son
M
M
Lee
D S
DS
Chung
J K
JK
Park
J H
JH
Lee
M C
MC
D000818:Animals; D007459:Iodized Oil; D008099:Liver / Q000000981:diagnostic imaging / Q000378:metabolism; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008114:Liver Neoplasms, Experimental / Q000532:radiotherapy*; D008168:Lung / Q000378:metabolism; D051379:Mice; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011868:Radioisotopes; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012211:Rhenium; D012996:Solutions; D014018:Tissue Distribution
C431271:188Re 2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012996:Solutions; D012211:Rhenium; D007459:Iodized Oil